



Cite this: *Chem. Sci.*, 2024, 15, 7749

All publication charges for this article have been paid for by the Royal Society of Chemistry

Biosynthesis of the bacterial antibiotic 3,7-dihydroxytropolone through enzymatic salvaging of catabolic shunt products†

Lars Höing,^a Sven T. Sowa,^a Marina Toplak,^b Jakob K. Reinhardt,^c Roman Jakob,^c Timm Maier,^c Markus A. Lill^d and Robin Teufel^c   [✉]

The non-benzenoid aromatic tropone ring is a structural motif of numerous microbial and plant natural products with potent bioactivities. In bacteria, tropone biosynthesis involves early steps of the widespread CoA-dependent phenylacetic acid (paa) catabolon, from which a shunt product is sequestered and surprisingly further utilized as a universal precursor for structurally and functionally diverse tropone derivatives such as tropodithietic acid or (hydroxy)tropolones. Here, we elucidate the biosynthesis of the antibiotic 3,7-dihydroxytropolone in Actinobacteria by *in vitro* pathway reconstitution using paa catabolic enzymes as well as dedicated downstream tailoring enzymes, including a thioesterase (TrIF) and two flavoprotein monooxygenases (TrICD and TrIE). We furthermore mechanistically and structurally characterize the multifunctional key enzyme TrIE, which mediates an unanticipated *ipso*-substitution involving a hydroxylation and subsequent decarboxylation of the CoA-freed side chain, followed by ring oxidation to afford tropolone. This study showcases a remarkably efficient strategy for 3,7-dihydroxytropolone biosynthesis and illuminates the functions of the involved biosynthetic enzymes.

Received 13th March 2024

Accepted 21st April 2024

DOI: 10.1039/d4sc01715c

rsc.li/chemical-science

Introduction

Tropone (2,4,6-cycloheptatrien-1-one) natural products have potent bioactivities against cancer cells, microorganisms and viruses and are generated by fungi, plants and bacteria *via* unrelated biosynthetic pathways. In bacteria, tropone formation was previously shown to surprisingly depend on a catabolic pathway that normally enables aerobic growth on various aromatic compounds such as styrene, 2-phenylethylamine or phenylalanine.¹ Typically, these aromatics get converted into phenylacetic acid (paa), which is then further degraded into the central metabolites succinyl-CoA and acetyl-CoA by the widespread pathway (Fig. 1).^{2–4} This process first involves the activation of paa by phenylacetyl-CoA synthetase (PaaK; encoded, *e.g.*, by the *paa* gene cluster in *Escherichia coli* K12) to phenylacetyl-CoA (1), followed by the epoxidation of the phenyl ring by a diiron-dependent multicomponent monooxygenase

(PaaABCE)^{5,6} and the isomerization to oxepin-CoA by an enoyl-CoA isomerase (PaaG).⁷ The enol ether moiety of this oxepin ring is subsequently hydrolysed by a bifunctional fusion protein (PaaZ), consisting of an N-terminal aldehyde dehydrogenase (ALDH) and a C-terminal (*R*)-specific (MaoC-like) enoyl-CoA hydratase (ECH) domain.¹ Following ECH-mediated ring cleavage, the produced highly reactive semialdehyde intermediate 2 is rapidly oxidized to the stable carboxylic acid by the ALDH domain, which is facilitated through substrate channeling,⁸ before further final β -oxidation-like degradation steps.^{1,2} However, in a competing side reaction, 2 may also undergo a rapid non-enzymatic intramolecular Knoevenagel condensation to the shunt product dihydrotropone-2-carboxyl-CoA (2-hydroxycyclohepta-1,4,6-triene-1-carboxyl-CoA; (3)). Accidental formation of this shunt product cannot be entirely prevented by PaaZ, thus necessitating strategies to recover the trapped CoA in the bacteria.¹ Typically, this is achieved *via* a 3-specific thioesterase (PaaY),⁵ while some bacteria instead use 3 as a precursor for the production of diverse secondary metabolites, which frees CoA in the course of the corresponding downstream biosynthetic steps.^{1,9}

Aside from rare tropone-containing aromatic polyketides,¹⁰ the vast majority of bacterial tropones likely derive from the universal precursor 3.⁹ Examples are tropone derivatives such as the virulence factor tropolone (2-hydroxytropone; 4) from the plant pathogen *Burkholderia* spp.^{11–13} or 7-hydroxytropolone (5) and 3,7-dihydroxytropolone (6) from *Streptomyces neyagawaensis*

^aPharmaceutical Biology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland. E-mail: robin.teufel@unibas.ch

^bHilde-Mangold-Haus (CIBSS), University of Freiburg, Habsburgerstrasse 49, 79104 Freiburg im Breisgau, Germany

^cBiozentrum, University of Basel, Spitalstrasse 41, 4056 Basel, Switzerland

^dComputational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4sc01715c>




Fig. 1 Bacterial *paa* catabolic pathway and biosynthesis of **6** as elucidated herein. Catabolic steps produce reactive **2**, which is either converted into central metabolites (grey arrows; catabolic route) or spontaneously cyclizes to the tropone-precursor **3** (black arrows; biosynthetic route). In *Streptomyces* spp., **3** is further converted into **6** involving pathway-specific enzymes encoded by the *trl* gene cluster, with FPMO TrIE (red dashed box) as key enzyme (see text for details). Oxygen atoms shown in red and blue indicate incorporation from O_2 and H_2O , respectively. Note that the carbon numbering for all compounds is according to compound **6**.

and *S. tropolofaciens* No. K611-97, respectively.^{14–16} Typically, (di) hydroxylated tropolones have strong cytotoxic, antimicrobial and antiviral activities when three adjacent oxygens are present, which allows chelation of up to two metal ions (e.g., Fe^{2+} , Zn^{2+} , Cu^{2+} , Mg^{2+}) and thus enables the (un)competitive inhibition of (bi) metallic enzymes such as the medically relevant inositol mono-phosphatase, matrix metalloproteases and virulence factors (e.g., anthrax lethal factor or HIV reverse transcriptase).⁹ Compound **5**, e.g., was shown to inhibit the initiation of DNA synthesis of the hepatitis B virus¹⁷ and is furthermore highly cytotoxic against cultured B16 melanoma cells, thereby substantially extending the life span of mice with B16 melanoma.¹⁵ Recent studies suggest that the cytotoxic effects of tropolones (in multiple myeloma cells) may be due to the alteration of cellular iron availability.¹⁸ Compound **5** was also shown to be synergistic with aminoglycoside antibiotics *in vitro* when administered against resistant bacteria due to the inhibition of the aminoglycoside-inactivating enzyme 2'-O-adenylyltransferase, likely by chelating two catalytically important Mg^{2+} ions.^{9,14,16} While **5** and **6** were discovered several decades ago, a biosynthetic gene cluster (BGC) was only recently identified for **6** biosynthesis in *S. cyaneofuscatus* Soc7 (Table S1†) and *S. luteogriseus* Slg41, which produce **6** at very high titers compared to the originally reported producer *S. tropolofaciens* No. K611-97.¹⁹ Activity guided cosmid screening and heterologous expression in *S. coelicolor* M1152 revealed a set of distinct co-localized genes required for formation of **6** in these bacteria, as confirmed by comprehensive gene inactivation experiments.¹⁹ This identified BGC allows the bacteria to produce **6** *via* key intermediate **3**, in conjunction with the genes from early *paa* catabolism. Here we reconstitute **6** biosynthesis *in vitro* using heterologously produced enzymes and unravel unexpected enzyme functionalities, in particular for flavoprotein monooxygenase (FPMO) TrIE, which was mechanistically and structurally investigated and shown to catalyze an unusual reaction sequence comprising an *ipso*-substitution of the carboxyl side chain for a hydroxyl group and a final two-electron ring oxidation.

Results & discussion

The 3,7-dihydroxytropolone biosynthetic gene cluster is widespread in actinobacteria

The biosynthesis of **6** *via* the *trl* BGC suggested that (hydroxy) tropolones in Actinobacteria are produced from *paa*-derived **3**, which has recently also been shown for Gram-negative *Burkholderia* sp.¹² and presumably *Pseudomonas* sp.²⁰ Accordingly, formation of the virulence factor **4** in the rice pathogen *B. plantarii*^{11,13} involves a functional homologue of flavoprotein TdaE from tropodithietic acid biosynthesis,^{9,21–23} which functions as a highly unusual dioxygenase¹² and is structurally related to acyl-CoA dehydrogenases (rather than typical oxygenases). TdaE converts **3** *via* ring oxidation, CoA-ester oxygenolysis and epoxidation into a highly reactive compound, which spontaneously decarboxylates to **4** (*vide infra*). In contrast, the *trl* BGC encodes seemingly classical FPMOs such as TrIE and TrICD. To further investigate the occurrence of the *trl* BGC in bacteria, a pBLAST²⁴ was performed using TrIE as a query. This allowed the identification of several highly similar BGCs in *Streptomyces* spp., but also other Actinobacteria such as *Amycolatopsis regifaucium* or *Longimycelium tulufanense* from the Pseudonocardiaceae family (Fig. 2), which were both obtained and cultivated. After testing various culture conditions, **5** and **6** could indeed be identified in *L. tulufanense* *via* LC-MS analysis and based on their distinct UV-vis spectra (Fig. S1 and S2†), whereas *A. regifaucium* apparently lacked tropolone production, showing that the strategy for the biosynthesis of hydroxylated tropolones is widespread in Actinobacteria and possibly dependent on specific environmental influences.

Enzymatic formation of **3** and the role of putative ECH TrIA

To gain further insights into the underlying enzymology for **6** formation, we first reconstituted oxepin-CoA biosynthesis *in vitro* using chemically synthesized **1** and heterologously produced PaaABCE and PaaG, according to previous






Fig. 2 Alignment of the predicted *trl* gene clusters identified in various Actinobacteria. Homologues are highlighted in the same color. Figure created with CAGECAT.²⁵

studies.^{1,2,12} Based on the homology of TrlA to PaaZ-ECH and the phenotype of the *trlA* deletion mutant,¹⁹ the same function was expected, that is, hydrolytic cleavage of oxepin-CoA yielding 3. The absence of an ALDH domain would thus result in the complete rerouting of the catabolic pathway to 5 biosynthesis. Surprisingly, however, no conversion of oxepin-CoA was observed upon addition of heterologously produced TrlA under all tested conditions (Fig. S3†). TrlA could be effortlessly produced in *E. coli* BL21 and purified; moreover, it seemed properly folded and stable. We therefore scrutinized its amino acid sequence and compared it with PaaZ-ECH and related enzymes (Fig. S4†). Important catalytic residues for water activation (H38, D33) and oxyanion hole formation (G56) were conserved, implying full hydratase functionality. We speculate that TrlA may be directly regulated *in vivo* on the enzymatic level by an unknown mechanism, possibly allowing a controlled switch from aromatic catabolism to 5 biosynthesis in *Streptomyces* spp. To investigate downstream 5-biosynthetic enzymes, we thus utilized a PaaZ-E256Q variant with a dysfunctional ALDH domain¹ to generate 2.

TrlF is homologous to PaaY and functions as 3-specific thioesterase

We next explored the role of TrlF. Deletion of *trlF* abolished 5 production and furthermore suggested a role for TrlF early in the processing of 3, proposed as an oxidative decarboxylation of the CoA-freed side-chain of a 3-derived intermediate affording tropone.¹⁹ However, when TrlF was added to the enzyme assays, the direct conversion of 3 into dihydrotropone-2-carboxylate (7) was observed, as verified by UPLC-HRMS analysis and comparison to a chemically synthesized standard (*i.e.* tropone-2-carboxylate, which could be converted into 7 by chemical oxidation, see ESI Fig. S5 and S6†). Tropone, in contrast, was

only observed in minor amounts in the assays, arising from the spontaneous decarboxylation and oxidation of 7, similar to previous observations from bacterial mutant strains lacking the ALDH functionality for processing of 2.²⁶ When analyzing the protein sequence of TrlF, we noticed that it is homologous to PaaY from paa catabolism, which was previously shown to function as a zinc-dependent thioesterase⁵ with the structural (active site) architecture of γ -carbonic anhydrases^{27,28} (Fig. S7†). PaaY orthologs were confirmed to be homotrimers,^{27,28} whose biological role is to hydrolyze the thioester of shunt product 3 and thus to counteract the depletion of CoA during paa catabolism.⁵ These enzymes contain one central Ca^{2+} and three Zn^{2+} at the interface between the monomers,²⁷ which likely have both structural and catalytic roles equivalent to carbonic anhydrases. Interestingly, PaaY from *E. coli* was reported to lack carbonic anhydrase functionality,²⁸ as opposed to the respective ortholog from the human pathogen *Acinetobacter baumannii* (for which a functional paa catabolon is important for virulence²⁷) that also catalyzed the interconversion of CO_2 and HCO_3^- ; additionally, both enzymes differed in their specificity for acyl-CoA-esters.^{5,27} We could observe carbonic anhydrase activity of TrlF from *S. cyaneofuscatus* Soc7 based on a photometric test using the pH indicator dye phenol red in saturated CO_2 solution with a specific activity of $\sim 0.57 \mu\text{mol min}^{-1} \text{mg}^{-1}$ (Fig. S8†). The underlying catalytic mechanism of PaaY orthologs and TrlF most likely corresponds to the moonlighting functionality of some carbonic anhydrases that cleave thioesters *via* nucleophilic attack of an active site Zn^{2+} -bound hydroxide ion on the carbonyl of the thioester moiety.²⁹

TrlE is a multifunctional key tailoring enzyme

For catalysis of the next pathway step presumably involving a ring hydroxylation, the predicted FPMO TrlE seemed a prime

candidate. In general, flavoenzymes are specific for flavin mononucleotide (FMN) or flavin adenine dinucleotide (FAD). Heterologously produced and purified TrIE exhibited yellow color and a UV-vis spectrum indicative of bound flavin, which was identified *via* HPLC-DAD as FAD by comparison with a standard (Fig. S9†). The $\Delta trIE$ mutant strain accumulated mainly tropone, which was accordingly proposed as substrate for the production of **4** *via* hydroxylation.¹⁹ However, TrIE with NADPH could not convert tropone; instead, the enzyme surprisingly accepted the TrIF-product **7** and generated **4** without accumulation of apparent intermediates, as shown by RP-HPLC, LC-MS (Fig. 3) and comparison with a commercially available standard (Fig. S10–S12†). In this reaction, minor amounts of tropone were found, most probably resulting from the spontaneous decomposition of the TrIF-produced **7** (as described above), which could also explain tropone-accumulation in the $\Delta trIE$ mutant strain.

This unexpected result implied that TrIE catalyzes several steps in **6** biosynthesis, including an *ipso*-substitution initiated by C1-hydroxylation that enables the subsequent side-chain elimination *via* decarboxylation with the ring ketone acting as electron sink, before a final two-electron ring oxidation generates aromatic **4**. ¹⁸O-isotope labelling experiments confirmed the incorporation of O₂-derived oxygen into the substrate and thus verified TrIE's oxygenase functionality (Fig. S13†). Based on sequence comparison and phylogenetic analysis, TrIE belongs to the group A FPMOs that typically feature a mobile flavin cofactor with distinctive “OUT” and “IN” conformations, enabling flavin reduction (in the presence of the native substrate) and substrate hydroxylation, respectively.^{30,31} Microbial group A FPMOs are widely found in natural product biosynthetic pathways and particularly oxygenate activated substrates, *e.g.*, *via* hydroxylation of phenolic moieties or Baeyer–Villiger oxygenations of ketones.^{31–33} Sequence comparison and a phylogenetic tree (Fig. S14, S15 and Table S2†) revealed that TrIE is closely related to enzymes from catabolic pathways, including salicylate hydroxylases from various *Pseudomonas putida* strains (*e.g.*, SalH³⁴ and NahG³⁵) that convert salicylate into catechol, 3-hydroxybenzoate 6-hydroxylase (3HB6H) from *Rhodococcus jostii*,³⁶ or 6-hydroxynicotinate 3-monooxygenase (NicC) from *Pseudomonas putida* KT2440 and other strains.^{37,38} The only other enzyme involved in natural product biosynthesis is TropB from *Talaromyces stipitatus* catalyzing an oxidative phenol dearomatization in the biosynthesis of the fungal tropolone natural product stipitatic acid (which is biosynthetically unrelated to bacterial tropolones).^{39–41} Interestingly, in this case, the tropolone ring is formed in downstream steps by a non-heme Fe(II)-dependent dioxygenase TropC *via* an oxidative ring expansion.⁴⁰

To gain more insights into the underlying catalytic mechanism of TrIE, further mechanistic and structural investigation was conducted starting with protein crystallization. Following extensive screening, yellow TrIE crystals indicative of bound FAD could be obtained that diffracted up to 2.5 Å (Table S3†). The structure was solved *via* molecular replacement and showed that TrIE features the typical glutathione reductase (GR-2) type Rossmann fold of group A FPMOs with two distinct




Fig. 3 (A) RP-HPLC chromatograms at 300 nm showing the conversion of **7** (highlighted in blue) into **4** (highlighted in yellow) by TrIE. (B) Plotted data from (A) showing relative amounts of **4** and **7** in % (area under the peak) against time. (C) UV-vis and MS spectra of **4** (identical to commercially available **4** standard) and of **7**.

domains I and II involved in FAD and substrate binding, respectively (Fig. 4A). The non-covalently bound FAD observed in this structure is present in the “IN” conformation, in which the isoalloxazine moiety faces the proposed substrate binding site.

Interestingly, the active site of TrIE with residues R185, Y217 and H213 most closely resembles TropB, 3HB6H and NicC (rather than SalH/NahG), implying similar mechanisms for substrate binding and activation in these enzymes (Fig. 4B). To further investigate the substrate binding and activation by TrIE, co-crystallization and soaking of the protein crystals with **7** was attempted. While TrIE readily crystallized with bound FAD, no complex structure with the substrate could be obtained. Similar attempts with the substrate analogues tropone-2-carboxylate and salicylate also remained unsuccessful, although binding




Fig. 4 Structure of TrIE with FAD in the IN conformation and predicted binding mode of **7**. (A) Overall structure of TrIE comprising the FAD-binding domain (domain I; green; residues 1–71, 105–177 and 278–400) and the substrate binding domain (domain II; orange; residues 72–104 and 178–287). A dashed box indicates the location of the active site. (B) Comparison of corresponding active site residues from structural alignments with SalH (PDB ID: 5EVY), 3-hydroxybenzoate 6-hydroxylase (3HB6H; PDB ID: 4BJZ), TropB (PDB ID: 6NET) and NicC (PDB ID: 5EOW). (C) Predicted binding mode of **7** in the active site of TrIE. The TrIE structure resulting from molecular dynamics simulation (white) is shown aligned to the experimental crystal structure (orange, green, yellow). Potential hydrogen bonds are indicated as black dashes. The distance between C₁ in **7** to C_{4α} in FAD after molecular dynamics simulation is highlighted with magenta dashes. Distances are shown in Ångström.

of these compounds to TrIE was confirmed by differential scanning fluorimetry (DSF) (Fig. S16–S18 and Table S4†).

To further investigate the structural basis for substrate binding and activation, a molecular model was generated for **7** interacting with TrIE. Flexible molecular docking of **7** into the obtained crystal structure of TrIE was conducted. Throughout a subsequent 100 ns molecular dynamics simulation, the position of **7** remained in the proposed substrate binding pocket nearby the isoalloxazine moiety of the FAD (Fig. S19†). Similar binding positions were also observed for the native substrates in the respective crystal structures of SalH, 3HB6H and TropB (Fig. S20†). For our analysis, we chose a representative binding mode of **7** (Fig. 4C).

These results suggest a plausible substrate binding mode with the carboxylate group of **7** forming hydrogen bonds with the side-chains of R185 and Y217, while the ring system packs against a hydrophobic part of the pocket formed by L228 and I215. Compound **7** is ring hydroxylated at C₁, which is located approximately 5.6 Å from the flavin C_{4α} and thus fully in line with typical substrate orientations in FPMOs that employ the canonical flavin-C_{4α}-(hydro)peroxide for catalysis.^{30,42,43} Most likely, to lower the activation barrier for hydroxylation, first the activating adjacent ring hydroxyl group needs to become deprotonated, as similarly described, *e.g.*, for the prototype group A FPMO *para*-hydroxybenzoate hydroxylase.⁴⁴ In the case of TrIE, this hydroxyl group of **7** points upwards towards the re-

side of the FAD-C_{4α}, adjacent to a loop with the sequence motif PHH (Fig. 4C). In some group A FPMOs, this loop plays an important role in substrate binding and is key for regulating the switch from the flavin “IN” into the “OUT” conformation.⁴⁵ For TrIE, no amino acid side chains point towards the hydroxyl group of **7**, however, the backbone nitrogen of H304 from this loop is suitably positioned at 3.4 Å distance (Fig. 4C) to stabilize the negative charge and thus promote an electrophilic attack of the flavin-C_{4α}-hydroperoxide onto the C₁ of **7**, generating a Wheland-like intermediate as described for SalH/NahG³⁵ (Fig. 5). Subsequently, the carboxylate group of **7**, whose negative charge is initially stabilized by the R185 and Y217 side chains, would be pushed towards a hydrophobic part of the pocket lined by L228, which would favor decarboxylation through electrostatic destabilization³⁵ and afford **4** as product following a final two-electron ring oxidation. Interestingly, such an oxidation step was not reported for any of the closely related catabolic enzymes that mediate similar *ipso*-substitutions. To investigate whether TrIE actively catalyzes this step or if it results from spontaneous oxidation by O₂, **4** was chemically reduced with sodium dithionite to obtain the proposed intermediate, before TrIE was added. Re-oxidation was spectroscopically monitored at 340 nm and clearly showed that intact TrIE led to the fastest formation of **4** compared to heat-inactivated enzyme or free FAD (Fig. S21 and S22†).




Fig. 5 Proposed catalytic mechanism of TrIE. Conversion of 7 into 4 via flavin- $C_{4\alpha}$ -hydroperoxide-mediated hydroxylation, followed by decarboxylation and FAD-dependent ring oxidation.

In SalH/NahG, H226 was proposed to serve as catalytic base; in TrIE, the corresponding H213 is however located approximately 8 Å from the hydroxyl group of 7, which makes a direct involvement in catalysis unlikely. In addition, Y217 is not conserved in these enzymes, instead a phenylalanine is present at the corresponding position. To investigate the role of both amino acids in TrIE catalysis, site directed mutagenesis was employed, generating the mutants H213A, H213E, H213Q and Y217F. Overall, the resulting variants showed reduced FAD loading upon purification and were less heat stable compared to the wild type (Fig. S16A†), while their hydrodynamic behavior during size-exclusion chromatography remained unaffected (Fig. S23†). While H213A lost the ability to produce 4 entirely, the other variants showed strongly reduced catalytic activity, with slowed substrate consumption and product formation compared to the wild-type enzyme (Fig. S24†). In our current model, Y217 contributes to substrate binding, but is not directly involved in catalysis. Therefore, the observed reduced catalytic activity seems plausible. For both H213E and H213Q variants, minor product formation was still observed, which, together with the proposed substrate positioning in the active site, indicates that this residue most likely plays only a subsidiary role in catalysis. The strongly reduced thermal stability in all H213 variants rather implies that this residue is important for the structural integrity of TrIE.

TrICD is a two-component FPMO producing 3,7-dihydroxytropolone as main product

The $\Delta trlC$ mutant strain accumulated 4 as main compound, implying that TrIC may act subsequent to TrIE and likely catalyzes two consecutive hydroxylations of 4 via 5 into 6.¹⁹ TrIC is

predicted to be the monooxygenase component of a two-component FPMO that relies on a separate enzyme, for flavin reduction, here TrID.^{46,47} As opposed to the corresponding monooxygenase constituents, these flavin reductases (fre) typically have higher affinity for oxidized rather than reduced flavins, thus ensuring efficient reductive and oxidative half reactions.^{46,47} Following the purification of the two separately heterologously produced enzymes TrIC and TrID, the cofactor specificity of TrID was analyzed. Accordingly, TrID preferred FAD and NADH over FMN and NADPH, respectively (Fig. S25†). This is consistent with the observation that a fraction of TrID was co-purified with bound FAD (Fig. S9†). When TrICD, FAD and NADH were added together to the *in vitro* enzyme mix, the TrIE-produced 4 was rapidly converted into a new compound (5); analogous results were obtained from separate TrICD assays without the other enzymes using commercially available 4 (Fig. S26 and S27†). Compound 5 was identified as 7-hydroxytropolone via UPLC-HRMS, NMR, and UV spectroscopy, fully consistent with previously published data¹⁴ (Table S5 and Fig. S28–32†). It is noteworthy that TrIC also generated 5 *in vitro* when TrID was substituted with the flavin reductase from *E. coli*, albeit product formation was slightly diminished (Fig. S33†). Interestingly, in contrast to $\Delta trlC$, *trlD* inactivation did not completely abolish product formation, leading to accumulation of 5 rather than 4 in the heterologous producer strain *S. coelicolor* M1152, suggesting that the loss of the flavin reductase TrID is to some extent complemented by the host strain (presumably by other flavin reductases). Notably, the final product 3,7-dihydroxytropolone (6) was observed in the TrICD assay after prolonged incubation time and only when an NADH regeneration system (consisting of sodium formate and formate dehydrogenase⁴⁸) was employed, as verified by LC-MS (Fig. S26




Fig. 6 Proposed mechanism for the dual hydroxylation of 4 by the two-component FPMO TrICD affording 6. See text for details.

and S34–S36†). Although the quantities of **6** obtained *in vitro* did not suffice for NMR measurements, the produced compound matched previously reported physicochemical properties of **6** and also the compound produced by *L. tulufanensis* in this work.

Notably, the complete *in vitro* pathway reconstitution of **6** biosynthesis could be achieved, allowing the complete one-pot conversion of **1** into **6** by combining enzymes from early paa catabolism with the specific tropolone tailoring enzymes (Fig. S27†). Interestingly, **6** was only produced in spurious amounts when TrlD was substituted with flavin reductase from *E. coli* under the same conditions, which suggests the requirement of proper protein–protein-interactions between the two native redox partner enzymes for efficient catalysis. For **6** formation, we propose a mechanism involving two consecutive *ortho*-hydroxylations at C2 (activated by the C1-hydroxyl) and the adjacent C3 (enabled by the newly introduced C2-hydroxyl), which would make substrate re-positioning of **5** likely superfluous within the active site of TrlC for the second hydroxylation reaction (Fig. 6). Further insights into the underlying mechanism will require detailed structural and mechanistic studies of TrlCD.

Conclusion

In summary, for the first time a complete bacterial tropone biosynthetic pathway could be reconstituted *in vitro* using a combination of 3-producing paa catabolic enzymes as well as enzymes specific for the formation of **4**, **5** and **6**, *i.e.* thioesterase TrlF and the FPMOs TrlE and TrlCD, whose functions could be assigned and investigated in detail. The strategy for formation of hydroxylated tropolones thus relies on an unusual intertwining of enzymes from primary and secondary metabolism. While the biosynthesis of unmodified **4** from **3** in Gram-negative bacteria has been recently linked to the action of the non-canonical flavoprotein dioxygenase TdaE that structurally resembles acyl-CoA dehydrogenases,¹² herein we describe a structurally and functionally unrelated group A FPMO TrlE from Gram-positive Actinobacteria with GR-2 type Rossmann fold as key enzyme for **4** formation. In contrast to TdaE orthologs, which produce a highly reactive epoxide that is prone to undergo spontaneous decarboxylation, TrlE directly controls side-chain elimination *via* the herein identified *ipso*-substitution. Notably, both enzymes catalyze multiple reactions and combine oxidation reactions that do not involve oxygen-transfer to the substrate (normally facilitated by dedicated flavoprotein oxidases or dehydrogenases) with distinct oxygenation chemistry. While TdaE may rely on non-canonical flavin-N₅-oxygen adducts for oxygen transfers,^{12,49,50} TrlE most likely employs the flavin-C_{4a}-hydroperoxide for hydroxylation and represents a novel multitasking FPMO in natural product biosynthesis that consecutively catalyzes not only hydroxylation and decarboxylation but a two-electron ring oxidation as well. In conjunction with the elucidation of the role of TrlCD, these results underscore the predominant roles of flavoenzymes in the construction and redox tailoring of microbial natural product skeletons such as tropones³² and open new possibilities for the bioengineering of tropolone pathways and the generation of novel derivatives.

Data availability

The X-ray crystallography structure of TrlE was deposited at the RCSB Protein Data Bank (PDB) with the code 8RQH. All further relevant data can be found in this manuscript or the ESI.† Raw data is available at the Zenodo online repository or upon request.

Author contributions

Lars Höing: investigation, formal analysis, validation, visualization, writing – original draft, Sven T. Sowa: formal analysis, supervision, data curation, writing – review & editing, Marina Toplak: conceptualization, supervision, writing – review & editing, Jakob K. Reinhardt: formal analysis, writing – review & editing, Roman Jakob: formal analysis, data curation, writing – review & editing, Timm Maier: resources, writing – review & editing, Markus A. Lill: investigation, formal analysis, validation, writing – review & editing, Robin Teufel: project administration, conceptualization, supervision, funding acquisition, writing – original draft.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft (DFG) by grants TE 931/3-1 & TE 931/4-1 and the Swiss National Science Foundation (SNSF) by grant 212747 (all awarded to R. T.). We would like to thank the group of Prof. Jeroen Dickschat for providing tropone-2-carboxylic acid.

References

- 1 R. Teufel, C. Gantert, M. Voss, W. Eisenreich, W. Haehnel and G. Fuchs, *J. Biol. Chem.*, 2011, **286**, 11021–11034.
- 2 R. Teufel, V. Mascaraque, W. Ismail, M. Voss, J. Perera, W. Eisenreich, W. Haehnel and G. Fuchs, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 14390–14395.
- 3 E. R. Olivera, B. Minambres, B. Garcia, C. Muniz, M. A. Moreno, A. Ferrandez, E. Diaz, J. L. Garcia and J. M. Luengo, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 6419–6424.
- 4 A. Ferrandez, B. Minambres, B. Garcia, E. R. Olivera, J. M. Luengo, J. L. Garcia and E. Diaz, *J. Biol. Chem.*, 1998, **273**, 25974–25986.
- 5 R. Teufel, T. Friedrich and G. Fuchs, *Nature*, 2012, **483**, 359–362.
- 6 A. M. Grishin, E. Ajamian, L. Tao, L. Zhang, R. Menard and M. Cygler, *J. Biol. Chem.*, 2011, **286**, 10735–10743.
- 7 M. Spieker, R. Saleem-Batcha and R. Teufel, *ACS Chem. Biol.*, 2019, **14**, 2876–2886.
- 8 N. Sathyanarayanan, G. Cannone, L. Gakhar, N. Katagihallimath, R. Sowdhamini, S. Ramaswamy and K. R. Vinothkumar, *Nat. Commun.*, 2019, **10**, 4127.



- 9 Y. Duan, M. Petzold, R. Saleem-Batcha and R. Teufel, *ChemBioChem*, 2020, **21**, 2384–2407.
- 10 H. Guo, D. Roman and C. Beemelmanns, *Nat. Prod. Rep.*, 2019, **36**, 1137–1155.
- 11 K. Azegami, K. Nishiyama, Y. Watanabe, I. Kadota, A. Ohuchi and C. Fukazawa, *Int. J. Syst. Bacteriol.*, 1987, **37**, 144–152.
- 12 Y. Duan, M. Toplak, A. Hou, N. L. Brock, J. S. Dickschat and R. Teufel, *J. Am. Chem. Soc.*, 2021, **143**, 10413–10421.
- 13 M. Wang, S. Tachibana, Y. Murai, L. Li, S. Y. Lau, M. Cao, G. Zhu, M. Hashimoto and Y. Hashidoko, *Sci. Rep.*, 2016, **6**, 22596.
- 14 H. A. Kirst, G. G. Marconi, F. T. Counter, P. W. Ensminger, N. D. Jones, M. O. Chaney, J. E. Toth and N. E. Allen, *J. Antibiot.*, 1982, **35**, 1651–1657.
- 15 K. Sugawara, M. Ohbayashi, K. Shimizu, M. Hatori, H. Kamei, M. Konishi, T. Oki and H. Kawaguchi, *J. Antibiot.*, 1988, **41**, 862–868.
- 16 N. E. Allen, W. E. Alborn Jr, J. N. Hobbs Jr and H. A. Kirst, *Antimicrob. Agents Chemother.*, 1982, **22**, 824–831.
- 17 E. Bak, J. T. Miller, A. Noronha, J. Tavis, E. Gallicchio, R. P. Murelli and S. F. J. Le Grice, *Molecules*, 2020, **25**, 4434.
- 18 S. L. Haney, M. L. Varney, H. R. Safranek, Y. S. Chhonker, G. D. N. G. Talmon, D. J. Murry, A. J. Wiemer, D. L. Wright and S. A. Holstein, *Leuk. Res.*, 2019, **77**, 17–27.
- 19 X. Chen, M. Xu, J. Lu, J. Xu, Y. Wang, S. Lin, Z. Deng and M. Tao, *Appl. Environ. Microbiol.*, 2018, **84**, e00349.
- 20 Z. Jiang, M. Chen, X. Yu and Z. Xie, *BioMetals*, 2016, **29**, 817–826.
- 21 N. L. Brock, A. Nikolay and J. S. Dickschat, *Chem. Commun.*, 2014, **50**, 5487–5489.
- 22 M. Berger, N. L. Brock, H. Liesegang, M. Dogs, I. Preuth, M. Simon, J. S. Dickschat and T. Brinkhoff, *Appl. Environ. Microbiol.*, 2012, **78**, 3539–3551.
- 23 H. Geng, J. B. Bruhn, K. F. Nielsen, L. Gram and R. Belas, *Appl. Environ. Microbiol.*, 2008, **74**, 1535–1545.
- 24 M. H. Medema, E. Takano and R. Breitling, *Mol. Biol. Evol.*, 2013, **30**, 1218–1223.
- 25 M. van den Belt, C. Gilchrist, T. J. Booth, Y. H. Chooi, M. H. Medema and M. Alanjary, *BMC Bioinf.*, 2023, **24**, 181.
- 26 R. Rost, S. Haas, E. Hammer, H. Herrmann and G. Burchhardt, *Mol. Genet. Genomics*, 2002, **267**, 656–663.
- 27 M. Jiao, W. He, Z. Ouyang, Q. Qin, Y. Guo, J. Zhang, Y. Bai, X. Guo, Q. Yu, J. She, P. M. Hwang, F. Zheng and Y. Wen, *Structure*, 2023, **31**, 935–947.
- 28 C. Fernandez, E. Diaz and J. L. Garcia, *Environ. Microbiol. Rep.*, 2014, **6**, 239–250.
- 29 M. Tanc, F. Carta, A. Scozzafava and C. T. Supuran, *ACS Med. Chem. Lett.*, 2015, **6**, 292–295.
- 30 M. Toplak, A. Matthews and R. Teufel, *Arch. Biochem. Biophys.*, 2021, **698**, 108732.
- 31 C. E. Paul, D. Eggerichs, A. H. Westphal, D. Tischler and W. J. H. van Berkel, *Biotechnol. Adv.*, 2021, **51**, 107712.
- 32 M. Toplak and R. Teufel, *Biochemistry*, 2022, **61**, 47–56.
- 33 M. Toplak, R. Saleem-Batcha, J. Piel and R. Teufel, *Angew. Chem. Int. Ed. Engl.*, 2021, **60**, 26960–26970.
- 34 T. Uemura, A. Kita, Y. Watanabe, M. Adachi, R. Kuroki and Y. Morimoto, *Biochem. Biophys. Res. Commun.*, 2016, **469**, 158–163.
- 35 D. M. A. Costa, S. V. Gomez, S. S. de Araujo, M. S. Pereira, R. B. Alves, D. C. Favaro, A. C. Hengge, R. A. P. Nagem and T. A. S. Brandao, *Int. J. Biol. Macromol.*, 2019, **129**, 588–600.
- 36 S. Montersino, R. Orru, A. Barendregt, A. H. Westphal, E. van Duijn, A. Mattevi and W. J. H. van Berkel, *J. Biol. Chem.*, 2013, **288**, 26235–26245.
- 37 S. W. Perkins, M. Z. Hlaing, K. A. Hicks, L. J. Rajakovich and M. J. Snider, *Biochemistry*, 2023, **62**, 1553–1567.
- 38 K. A. Hicks, M. E. Yuen, W. F. Zhen, T. J. Gerwig, R. W. Story, M. C. Kopp and M. J. Snider, *Biochemistry*, 2016, **55**, 3432–3446.
- 39 A. al Fahad, A. Abood, T. J. Simpson and R. J. Cox, *Angew. Chem. Int. Ed. Engl.*, 2014, **53**, 7519–7523.
- 40 J. Davison, A. al Fahad, M. Cai, Z. Song, S. Y. Yehia, C. M. Lazarus, A. M. Bailey, T. J. Simpson and R. J. Cox, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 7642–7647.
- 41 A. R. Benitez, S. E. Tweedy, S. A. B. Dockrey, A. L. Lukowski, T. Wymore, D. Khare, C. L. Brooks, B. A. Palfey, J. L. Smith and A. R. H. Narayan, *ACS Catal.*, 2019, **9**, 3633–3640.
- 42 P. Chaiyen, M. W. Fraaije and A. Mattevi, *Trends Biochem. Sci.*, 2012, **37**, 373–380.
- 43 H. A. Schreuder, W. G. J. Hol and J. Drenth, *Biochemistry*, 1990, **29**, 3101–3108.
- 44 B. Entsch, B. A. Palfey, D. P. Ballou and V. Massey, *J. Biol. Chem.*, 1991, **266**, 17341–17349.
- 45 B. A. Palfey, R. Basu, K. K. Frederick, B. Entsch and D. P. Ballou, *Biochemistry*, 2002, **41**, 8438–8446.
- 46 J. M. Robbins and H. R. Ellis, *Methods Enzymol.*, 2019, **620**, 399–422.
- 47 H. R. Ellis, *Arch. Biochem. Biophys.*, 2010, **497**, 1–12.
- 48 Z. Shaked and G. M. Whitesides, *J. Am. Chem. Soc.*, 1980, **102**, 7104–7105.
- 49 A. Matthews, R. Saleem-Batcha, J. N. Sanders, F. Stull, K. N. Houk and R. Teufel, *Nat. Chem. Biol.*, 2020, **16**, 556–563.
- 50 R. Saleem-Batcha and R. Teufel, *Curr. Opin. Chem. Biol.*, 2018, **47**, 47–53.

